KR100603219B1 - 반합성 엑테이나시딘 - Google Patents

반합성 엑테이나시딘 Download PDF

Info

Publication number
KR100603219B1
KR100603219B1 KR1020007011112A KR20007011112A KR100603219B1 KR 100603219 B1 KR100603219 B1 KR 100603219B1 KR 1020007011112 A KR1020007011112 A KR 1020007011112A KR 20007011112 A KR20007011112 A KR 20007011112A KR 100603219 B1 KR100603219 B1 KR 100603219B1
Authority
KR
South Korea
Prior art keywords
mammalian
compound
excipient
pharmaceutically acceptable
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020007011112A
Other languages
English (en)
Korean (ko)
Other versions
KR20010074474A (ko
Inventor
케네쓰 엘. 리네하트
죠스 제이. 모랄스
Original Assignee
더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 filed Critical 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈
Publication of KR20010074474A publication Critical patent/KR20010074474A/ko
Application granted granted Critical
Publication of KR100603219B1 publication Critical patent/KR100603219B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Separation Of Suspended Particles By Flocculating Agents (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Furan Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Hydrogenated Pyridines (AREA)
  • Dental Preparations (AREA)
KR1020007011112A 1998-04-06 1999-04-05 반합성 엑테이나시딘 Expired - Fee Related KR100603219B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8080298P 1998-04-06 1998-04-06
US60/080,802 1998-04-06

Publications (2)

Publication Number Publication Date
KR20010074474A KR20010074474A (ko) 2001-08-04
KR100603219B1 true KR100603219B1 (ko) 2006-07-20

Family

ID=22159716

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020007011112A Expired - Fee Related KR100603219B1 (ko) 1998-04-06 1999-04-05 반합성 엑테이나시딘

Country Status (27)

Country Link
US (1) US6124293A (enExample)
EP (2) EP1067933B1 (enExample)
JP (1) JP4443043B2 (enExample)
KR (1) KR100603219B1 (enExample)
CN (1) CN1157189C (enExample)
AT (1) ATE370148T1 (enExample)
AU (1) AU758100B2 (enExample)
BG (1) BG65088B1 (enExample)
BR (1) BR9909488B1 (enExample)
CA (1) CA2327468C (enExample)
CY (1) CY1106988T1 (enExample)
CZ (1) CZ301083B6 (enExample)
DE (1) DE69936845T2 (enExample)
DK (1) DK1067933T3 (enExample)
ES (1) ES2292237T3 (enExample)
HU (1) HUP0104273A3 (enExample)
IL (2) IL138856A0 (enExample)
MX (1) MXPA00009840A (enExample)
NO (1) NO328147B1 (enExample)
NZ (1) NZ507350A (enExample)
PL (1) PL196809B1 (enExample)
PT (1) PT1067933E (enExample)
RU (1) RU2217432C2 (enExample)
SK (1) SK285669B6 (enExample)
TR (1) TR200002921T2 (enExample)
UA (1) UA59439C2 (enExample)
WO (1) WO1999051238A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985876A (en) * 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
IL139607A0 (en) * 1998-05-11 2002-02-10 Pharma Mar Sa Metabolites of ecteinascidin 743
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MY130271A (en) * 1999-05-14 2007-06-29 Pharma Mar Sa Hemisynthetic method and new compounds
EP1254140A4 (en) 2000-01-19 2003-03-12 Univ Columbia SAFRAMYCIN-ECTEINASCIDIN SERIES COMPOUNDS, USAGE AND SYNTHESIS THEREOF
US7919493B2 (en) * 2000-04-12 2011-04-05 Pharma Mar, S.A. Anititumoral ecteinascidin derivatives
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
JP2004529074A (ja) 2000-11-03 2004-09-24 プレジデント アンド フェロウズ オブ ハーバード カレッジ サフラマイシン、そのアナログ、およびその使用
WO2002036135A2 (en) * 2000-11-06 2002-05-10 Pharma Mar, S.A. Compositions for antitumour treatment containing ecteinascidin 743
GB0117402D0 (en) 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
GB0119243D0 (en) 2001-08-07 2001-10-03 Pharma Mar Sa Antitumoral analogs of ET-743
GB0202544D0 (en) * 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
JP2007511499A (ja) * 2003-11-13 2007-05-10 ファーマ・マール・エス・アー・ウー コンビネーション
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
JP2007511509A (ja) * 2003-11-14 2007-05-10 ファルマ・マール・ソシエダード・アノニマ Ｅｔ−７４３およびパクリタキセルの使用を含むガンの併用療法
JP2008505862A (ja) * 2004-07-09 2008-02-28 ファルマ、マール、ソシエダード、アノニマ 予後分子マーカー
WO2006035244A2 (en) * 2004-09-29 2006-04-06 Pharma Mar S.A., Sociedad Unipersonal Ecteinascidin compounds as anti -inflammatory agents
RS50822B (sr) * 2004-10-26 2010-08-31 Pharma Mar S.A., Sociedad Unipersonal Pegilovani lipozomalni doksorubicin u kombinaciji sa ekteinescidinom 743
KR101188691B1 (ko) 2004-10-29 2012-10-09 파르마 마르 에스.에이. 엑티나시딘 및 디사카라이드를 포함하는 제제
GB0522082D0 (en) 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
CN100355775C (zh) * 2006-01-20 2007-12-19 南方医科大学 一种海鞘多肽及其制备方法
WO2009050303A1 (en) * 2007-10-19 2009-04-23 Pharma Mar, S.A. Prognostic molecular markers for et-743 treatment
EP2786755A3 (en) 2010-11-12 2014-10-29 Pharma Mar S.A. Combination therapy with an antitumor alkaloid
RU2738741C2 (ru) * 2016-02-04 2020-12-16 Цзянсу Хэнжуй Медицин Ко., Лтд. Инъекционная фармацевтическая композиция, включающая трабектедин, для применения вне желудочно-кишечного тракта и способ её получения
LT3615544T (lt) 2017-04-27 2023-05-10 Pharma Mar S.A. Priešnavikiniai junginiai
CA3158733A1 (en) 2019-11-21 2021-05-27 Pilar Calvo Methods of treating small cell lung cancer with lurbinectedin formulations

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089273A (en) * 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
US5149804A (en) * 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
US5256663A (en) * 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
TW221441B (enExample) * 1991-01-25 1994-03-01 Taiho Pharmaceutical Co Ltd
US5440055A (en) * 1993-03-12 1995-08-08 Aphios Corporation Method and apparatus for extracting taxol from source materials
US5478932A (en) * 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US5721362A (en) * 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds

Also Published As

Publication number Publication date
CZ20003650A3 (en) 2001-06-13
KR20010074474A (ko) 2001-08-04
HUP0104273A2 (hu) 2002-03-28
ATE370148T1 (de) 2007-09-15
BG104902A (en) 2001-07-31
JP4443043B2 (ja) 2010-03-31
BR9909488A (pt) 2000-12-26
CN1157189C (zh) 2004-07-14
AU3471399A (en) 1999-10-25
JP2002510633A (ja) 2002-04-09
CZ301083B6 (cs) 2009-11-04
DK1067933T3 (da) 2007-12-27
SK285669B6 (sk) 2007-06-07
NO20004978L (no) 2000-12-05
IL138856A0 (en) 2001-10-31
HK1033651A1 (en) 2001-09-14
NO20004978D0 (no) 2000-10-03
EP1067933A1 (en) 2001-01-17
HUP0104273A3 (en) 2003-12-29
DE69936845T2 (de) 2008-05-08
CA2327468C (en) 2008-05-06
AU758100B2 (en) 2003-03-13
CA2327468A1 (en) 1999-10-14
RU2217432C2 (ru) 2003-11-27
PL343439A1 (en) 2001-08-13
US6124293A (en) 2000-09-26
CY1106988T1 (el) 2012-09-26
EP1876180A2 (en) 2008-01-09
DE69936845D1 (de) 2007-09-27
RU2000128058A (ru) 2004-02-20
WO1999051238A1 (en) 1999-10-14
ES2292237T3 (es) 2008-03-01
PL196809B1 (pl) 2008-02-29
EP1067933B1 (en) 2007-08-15
NO328147B1 (no) 2009-12-21
NZ507350A (en) 2003-03-28
CN1304309A (zh) 2001-07-18
MXPA00009840A (es) 2002-04-24
BR9909488B1 (pt) 2011-02-08
EP1067933A4 (en) 2002-12-18
IL138856A (en) 2007-07-24
WO1999051238A9 (en) 2000-01-27
BG65088B1 (bg) 2007-02-28
EP1876180A3 (en) 2009-12-16
PT1067933E (pt) 2007-11-15
TR200002921T2 (tr) 2001-02-21
UA59439C2 (uk) 2003-09-15
SK15012000A3 (sk) 2001-08-06

Similar Documents

Publication Publication Date Title
KR20010074474A (ko) 반합성 엑테이나시딘
US5654426A (en) Ecteinascidins
EP0280741B1 (en) Mitomycin derivatives
KR100643092B1 (ko) 엑테인아시딘 743의 대사산물
EP0323171A2 (en) Novel K-252 derivatives having anti-tumor activity and pharmaceutical compositions containing them
IL96643A (en) 3 '- Dahmino -'S) - 2 ") - 3 (- Methoxy - 4" - Morpholinyl (-Docsorovicine chirley, its preparation and pharmaceutical preparations containing it
CN109796522A (zh) 海兔毒素10环肽衍生物及其制备方法和应用
KR920002141B1 (ko) 이합체 에피포도필로톡신 글루코사이드 유도체
US4831038A (en) Vinblastine derivatives and pharmaceutical composition containing them
US5661175A (en) Hemiasterlin and geodiamolide TA
EP0284380B1 (en) Mitomycin derivatives
DE60205470T2 (de) Analoge von 4-beta-1''-[(2''-(substitutierte-benzoyl)anilin]-podophyllotoxin zur verwendung als antikrebs-agentia 4-beta-1"-∫2"-(substituted benzoyl) anilino∫ podophyllotoxin analogues useful as anticancer agents
US4748251A (en) 7-n-aminomethylenemitomycin derivative
FI118767B (fi) Uudet akronysiinianalogit, menetelmä niiden valmistamiseksi ja niitä sisältävät farmaseuttiset koostumukset
HK1033651B (en) Semi-synthetic ecteinascidins
KR100390767B1 (ko) 아지리디닐퀴놀린디온 유도체와 그의 제조방법
KR101149095B1 (ko) 4-메틸헥사노 카할라리드 ｆ 화합물
JP2001527076A (ja) 海綿動物から単離されるアスマリンａ及びｂを含む細胞毒性アルカロイド誘導体

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20100630

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20110714

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20110714

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000